FibroBiologics director granted options on 30,803 shares
FibroBiologics, Inc. director Richard C. Cilento Jr. reported a grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
FibroBiologics, Inc. director Richard C. Cilento Jr. reported a grant of stock options. He received options to acquire 30,803 shares of common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting and expire on June 22, 2036.
Insider Trade Summary
Grant/Award: 30,803 shares
Grant/Award
1 txn
Insider
Cilento Richard C. Jr.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 30,803 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,803 contracts (Direct)
Footnotes (1)
- F1. The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
Key Figures
Option grant size: 30,803 shares
Exercise price: $0.7503 per share
Shares underlying options after grant: 30,803 shares
+1 more
4 metrics
Option grant size
30,803 shares
Stock options to acquire common stock
Exercise price
$0.7503 per share
Conversion or exercise price of options
Shares underlying options after grant
30,803 shares
Total derivative shares following transaction
Option expiration date
June 22, 2036
Final exercise date for the stock options
Key Terms
Stock Option (Right to Buy), conversion or exercise price, Grant, award, or other acquisition, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 0.7503"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
expiration date financial
"expiration_date: 2036-06-22T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting financial
"The options will vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did FibroBiologics (FBLG) report for Richard C. Cilento Jr.?
FibroBiologics reported a grant of stock options to director Richard C. Cilento Jr. He received options covering 30,803 shares of common stock as compensation, not an open-market purchase or sale of existing shares.
What is the exercise price of Richard C. Cilento Jr.’s FibroBiologics (FBLG) options?
The stock options have an exercise price of $0.7503 per share. This is the fixed price at which Mr. Cilento can purchase FibroBiologics common stock once the options vest and before they expire.
When do the new FibroBiologics (FBLG) stock options vest for Richard C. Cilento Jr.?
The options will vest in full on the earlier of the first anniversary of the grant date or the date of FibroBiologics’ next annual meeting, according to the footnote, making vesting time-based rather than performance-based.
When do Richard C. Cilento Jr.’s FibroBiologics (FBLG) stock options expire?
The granted stock options expire on June 22, 2036. After this expiration date, any unexercised portion of the 30,803 options will lapse, and Mr. Cilento will no longer be able to purchase shares under this grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
